Vera Therapeutics (VERA) Cash from Investing Activities (2020 - 2026)

Vera Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at -$137.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 999.76% year-over-year to -$137.8 million; the trailing twelve-month figure through Mar 2026 stood at $41.2 million (up 121.61% YoY), and the FY2025 full-year result was $194.3 million, up 145.71% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$137.8 million, down from $80.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $80.7 million in Q4 2025, with the low at -$221.4 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$28.1 million across 5 years, with a median of $12.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 5388.19% — and 2023, when it jumped 765.08%.
• Vera Therapeutics' Cash from Investing Activities stood at $13.4 million in 2022, then surged by 38.1% to $18.6 million in 2023, then slumped by 1293.05% to -$221.4 million in 2024, then surged by 136.44% to $80.7 million in 2025, then slumped by 270.85% to -$137.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$137.8 million (Q1 2026), $80.7 million (Q4 2025), and $69.8 million (Q3 2025), per Business Quant data.